With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. The 2024-25 Innovation Fund Seed Grants are currently open and you...
ECHO Spotlight Series: Panorama Health Leverages Wearable Technology to Combat Cardiovascular Disease
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...ECHO Spotlight Series: Revolutionizing Cardio-Oncology Care with Leynek Medical
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...ECHO Spotlight Series: AVA
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...ECHO Spotlight Series: Heart Squared’s Next-Generation Ventricular Assist Device
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...ECHO Spotlight Series: NorthMiRs and the Challenge of Sepsis-Induced Cardiac Dysfunction
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...World-first technology to clear the heart of dangerous protein deposits
‘Desperate need for therapies for AL amyloid cardiomyopathy’